Gundersenrich1089

The present study clarified the prevalence and risk factors of sleep disorders in visually impaired athletes.

A cross-sectional questionnaire survey was conducted with 99 visually impaired athletes engaged in the following Paralympic sport events track and field (marathon), goalball, swimming, blind soccer, and judo. Eighty-one respondents (male 72.8%; average age 32.5±12.0 years) who completed the survey were chosen for analyses. Survey items were attributes [age, gender, body mass index, and condition of visual impairment (athletic classification and causing time of disability)], lifestyle habits (bedtime, wake-up time, drinking alcohol, meals, and use of electronics after lights out), competition activities (sports time per week, morning and evening practices, and competition stressors), psychological distress, and sleep disorders [recorded using the Pittsburgh Sleep Quality Index (PSQI)]. First, the prevalence of the respondents having sleep disorders (scored 5.5 points or more in the PSQI) was investigated. Then, the relations between attributes, lifestyle habits, competition activities, psychological distress, and sleep disorders were explored using logistic regression analysis.

Twenty-six respondents (32.1%) had sleep disorders. Results of multivariate logistic regression analysis showed that "interpersonal relationship stressors" and "wake-up time" were independently related to sleep disorders.

Approximately one-third of visually impaired athletes were shown to have sleep disorders. High interpersonal relationship stressors and late wake-up time may be risk factors of their sleep disorders.

Approximately one-third of visually impaired athletes were shown to have sleep disorders. High interpersonal relationship stressors and late wake-up time may be risk factors of their sleep disorders.

The treatment landscape for anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) primarily involves ALK-directed tyrosine kinase inhibitors (TKIs). Although therapy with immune checkpoint inhibitors (ICIs) is a treatment option in NSCLC, the efficacy of ICI is inconclusive in ALK-positive NSCLC as a result of limited data. This retrospective real-world study sought to describe the characteristics of ALK-positive NSCLC patients treated with ICI and to assesses treatment outcomes in US oncology practices.

This analysis used the Flatiron Health electronic health record-derived deidentified database and included adult (18 years and older) ALK-positive advanced NSCLC patients with receipt of one or more ICIs after January 1, 2015. Median time to ICI discontinuation and real-world progression-free survival (rwPFS) were estimated by Kaplan-Meier methods.

Of 83 patients with ALK-positive NSCLC treated with ICIs, 50.6% (n= 42) received ICI without a prior ALK TKI. Median time to ICI discontinuation was 2.17 months (95% confidence interval, 1.41, 3.32). The median rwPFS was 2.34 months (95% confidence interval, 1.55, 3.09); in patients who received an ICI without prior ALK TKI, it was 3.9 months, and in patients who received ICI therapy after an ALK TKI, it was 1.5 months.

Real-world effectiveness (rwPFS) of ICIs in ALK-positive NSCLC patients, whether provided before or after TKIs, was limited, underscoring the relative lack of efficacy of ICI in this patient population, particularly compared to approved ALK TKIs.

Real-world effectiveness (rwPFS) of ICIs in ALK-positive NSCLC patients, whether provided before or after TKIs, was limited, underscoring the relative lack of efficacy of ICI in this patient population, particularly compared to approved ALK TKIs.

Optimal patient stratification is critical in the era of personalized medicine. Germline polymorphisms play an important role in the treatment response of various human diseases, including bladder cancer. Intravesical BCG therapy is widely-used for bladder cancer. However, tumor recurrence and progression are very common. Stratification based on germline polymorphisms may contribute to circumvent this clinical challenge. Autophagy pathway plays an important role in the nonspecific protective effects of BCG. Patients that carry C allele of rs3759601 in autophagy gene ATG2B showed increased risk of recurrence and progression in European population. DGalactose We thus sought to analyze rs3759601 and its relevance in BCG response in Asian NMIBC patients.

Functional impact of rs3759601 ATG2B (p.Gln1383Glu) was analyzed by bioinformatics programs including NCBI Conserved Domain Search, Clustal Omega, Polyphen and SIFT. NMIBC patients who received intravesical BCG at multiple hospitals in Singapore from 1995 to 2016 were ibladder cancer recurrence (P= 0.353, GC vs. GG hazard ratio [HR]= 1.324), or cancer progression (P= 0.454, GC vs. GG HR = 0.658).

In contrast to European NMIBC patients, ATG2B rs3759601 C allele is much less common in Asians and it not associated with BCG response in Asian NMIBC patients.

In contrast to European NMIBC patients, ATG2B rs3759601 C allele is much less common in Asians and it not associated with BCG response in Asian NMIBC patients.

Circulating tumor cells (CTC) have been demonstrated to have prognostic and predictive role in certain human cancers. However, studies exploring their role in metastatic renal cell carcinoma (mRCC) are scarce. We aimed to evaluate the prognostic and predictive role of CTC in mRCC.

In this prospective study, 35 patients with mRCC were analyzed for the presence of CTC before starting tyrosine kinase inhibitors (TKI). Progression-free and overall survival rates were estimated using the Kaplan-Meier curves and log-rank test. The prediction to TKI therapy was calculated with the response to treatment determined by standard imaging techniques.

Outcomes were assessed according to the CTC positivity at baseline, before the patients started TKI for mRCC. At a mean follow-up of 12.4 ± 4.1 months, disease progression was noted in 17 patients (48.6%) including 8 deaths (22.9%). CTC positive patients had a significantly lower progression-free survival rate (12.5% vs. 64.1%, respectively; P = 0.009) but not in the overall survival rate (75% vs.